KURA
KURA clinical trials: Kura Oncology, Inc.
Every trial on ClinicalTrials.gov where Kura Oncology, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 24
- Trials linked
- 18
- As lead sponsor
- 6
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
KURA on the catalyst calendar · KURA registry changes
- Primary completion Nov 2031Sponsor estimatePhase 3NCT07007312Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLKura Oncology, Inc. · Acute Myeloid Leukemia (AML)RecruitingKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2029Sponsor estimatePhase 1NCT07929740Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDSKura Oncology, Inc. · Myelodysplastic Syndrome (MDS)/AMLNot yet recruitingKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 1NCT06655246A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Kura Oncology, Inc. · Gastrointestinal Stromal Tumor (GIST)RecruitingKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsKura Oncology, Inc. · Solid Tumors With HRAS AlterationsRecruitingKURALeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2025ActualPhase 1/Phase 2NCT04997902Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)Kura Oncology, Inc. · HNSCCCompletedKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT06001788Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaKura Oncology, Inc. · AMLRecruitingKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05738538Expanded Access to ZiftomenibKura Oncology, Inc. · Acute Lymphoblastic Leukemia, With KMT2A RearrangementsAvailableKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04809233Expanded Access to TipifarnibKura Oncology, Inc. · HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)AvailableKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2028Sponsor estimatePhase 1/Phase 2NCT04067336First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc. · Advanced Malignant NeoplasmActive, not recruitingKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2030Sponsor estimatePhase 1NCT05735184A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or...Kura Oncology, Inc. · Acute Myeloid LeukemiaRecruitingKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 28, 2018ActualPhase 2NCT02779777Tipifarnib in Subjects With Myelodysplastic SyndromesKura Oncology, Inc. · Myelodysplastic SyndromesTerminatedKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2020ActualPhase 2NCT02807272Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaKura Oncology, Inc. · Leukemia, Myelomonocytic, ChronicCompletedKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2020ActualPhase 2NCT02383927Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsKura Oncology, Inc. · Thyroid CancerCompletedKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2021ActualPhase 2NCT02464228Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyKura Oncology, Inc. · Relapsed or Refractory Peripheral T-Cell LymphomaCompletedKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2, 2023ActualPhase 2NCT03719690Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyKura Oncology, Inc. · HRAS Gene MutationCompletedKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2, 2023ActualPhase 1NCT04865159Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid MalignanciesKura Oncology, Inc. · Advanced Solid TumorTerminatedKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 27, 2027Sponsor estimatePhase 1NCT05693090Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerKura Oncology, Inc. · NSCLCWithdrawnKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2, 2020ActualPhase 1NCT03051035First-in-Human Study of KO-947 in Non-Hematological MalignanciesKura Oncology, Inc. · Advanced Malignant NeoplasmTerminatedKURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1/Phase 2NCT05848687TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IITanja Andrea Gruber · Lymphoblastic LeukemiaRecruitingKURACollaboratorAMGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2028Sponsor estimatePhase 2NCT06930352Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard TherapyUma Borate · Acute Myeloid LeukemiaRecruitingKURACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2027Sponsor estimatePhase 1NCT07355335Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AMLMassachusetts General Hospital · KMT2A-rearrangedRecruitingKURACollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2033Sponsor estimatePhase 1NCT06376162Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute LeukemiaPedAL BCU, LLC · Relapsed/Refractory KMT2A-r Acute LeukemiaRecruitingKURACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimatePhase 1NCT06397027A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute...M.D. Anderson Cancer Center · Refractory Acute LeukemiaRecruitingKURACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimatePhase 1NCT06448013A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients...M.D. Anderson Cancer Center · Acute Myeloid LeukemiaRecruitingKURACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 24 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner